Search Results - "WOLINSKY, J. S"

Pathophysiology of multiple sclerosis and the place of teriflunomide by Gold, R., Wolinsky, J. S.

“…Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. 
Acta Neurol Scand: 2011: 124: 75–84.
© 2010 John Wiley & Sons A/S…”
Get full text

3D MPRAGE improves classification of cortical lesions in multiple sclerosis by Nelson, F, Poonawalla, A, Hou, P, Wolinsky, JS, Narayana, PA

“…Background Gray matter lesions are known to be common in multiple sclerosis (MS) and are suspected to play an important role in disease progression and…”
Get full text

Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial by FREEDMAN, M. S, WOLINSKY, J. S, SIMONSON, C, O'CONNOR, P. W, WAMIL, B, CONFAVREUX, C, COMI, G, KAPPOS, L, OLSSON, T. P, MILLER, A, BENZERDJEB, H, LI, H

“…To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). A total…”
Get full text

Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging by Nelson, F, Poonawalla, A.H, Hou, P, Huang, F, Wolinsky, J.S, Narayana, P.A

“…Accurate detection and classification of purely intracortical lesions in multiple sclerosis (MS) are important in understanding their role in disease…”
Get full text

Standardized MR imaging protocol for multiple sclerosis : Consortium of MS centers consensus guidelines by SIMON, J. H, LI, D, WOLINSKY, J. S, TRABOULSEE, A, COYLE, P. K, ARNOLD, D. L, BARKHOF, F, FRANK, J. A, GROSSMAN, R, PATY, D. W, RADUE, E. W

Get full text

MRI T2 lesion burden in multiple sclerosis : A plateauing relationship with clinical disability by LI, D. K. B, HELD, U, WOLINSKY, J. S, FILIPPI, M, PETKAU, J, DAUMER, M, BARKHOF, F, FAZEKAS, F, FRANK, J. A, KAPPOS, L, MILLER, D. H, SIMON, J. H

“…Previous studies have shown only modest correlation between multiple sclerosis (MS) lesions on MRI and clinical disability. To investigate the relationship…”
Get full text

Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes by FILIPPI, M, ROVARIS, M, ROCCA, M. A, SORMANI, M. P, WOLINSKY, J. S, COMI, G

“…The authors evaluated whether glatiramer acetate (GA) modifies the severity of tissue damage in 1,722 new lesions from 239 patients with MS enrolled in a…”
Get full text

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients by Ford, C C, Johnson, K P, Lisak, R P, Panitch, H S, Shifroni, G, Wolinsky, J S

“…A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study,…”
Get full text

Composite end points to assess delay of disability progression by MS treatments by Zhang, J, Waubant, E, Cutter, G, Wolinsky, JS, Leppert, D

“…Background: The Expanded Disability Status Scale (EDSS) has low sensitivity and reliability for detecting sustained disability progression (SDP) in multiple…”
Get full text

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis by SORMANI, M. P, ROVARIS, M, VALSASINA, P, WOLINSKY, J. S, COMI, G, FILIPPI, M

“…The measurement errors associated with two techniques for brain atrophy assessment in multiple sclerosis (MS) were estimated. The measurement error of a…”
Get full text

Composite MRI scores improve correlation with EDSS in multiple sclerosis by Poonawalla, AH, Datta, S., Juneja, V., Nelson, F., Wolinsky, JS, Cutter, G., Narayana, PA

“…Background: Quantitative measures derived from magnetic resonance imaging (MRI) have been widely investigated as non-invasive biomarkers in multiple sclerosis…”
Get full text

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability by JOHNSON, K. P, BROOKS, B. R, VOLLMER, T, WEINER, L. P, WOLINSKY, J. S, COHEN, J. A, FORD, C. C, GOLDSTEIN, J, LISAK, R. P, MYERS, L. W, PANITCH, H. S, ROSE, J. W, SCHIFFER, R. B

Get full text

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses by Petkau, J, Reingold, SC, Held, U, Cutter, GR, Fleming, TR, Hughes, MD, Miller, DH, McFarland, HF, Wolinsky, JS

“…Background Magnetic resonance imaging (MRI) of lesions in the brain may be the best current candidate for a surrogate biological marker of clinical outcomes in…”
Get full text

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis by FAZEKAS, F, BARKHOF, F, MILLER, D. H, FILIPPI, M, GROSSMAN, R. I, LI, D. K. B, MCDONALD, W. I, MCFARLAND, H. F, PATY, D. W, SIMON, J. H, WOLINSKY, J. S

“…MRI is very sensitive in showing MS lesions throughout the CNS. Using MRI for diagnostic purposes, however useful, is a complex issue because of limited…”
Get full text

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study by Sajja, B.R., Narayana, P.A., Wolinsky, J.S., Ahn, C.W., N/A, the PROMiSe Trial MRSI Group

“…Multicenter proton magnetic resonance spectroscopic imaging (MRSI) studies were performed on 58 primary progressive multiple sclerosis (PPMS) patients from…”
Get full text

Variable results after rituximab in neuromyelitis optica by Lindsey, J.W, Meulmester, K.M, Brod, S.A, Nelson, F, Wolinsky, J.S

“…Abstract Our objective was to assess the efficacy of rituximab (RTX) in neuromyelitis optica (NMO). We conducted a retrospective review of cases personally…”
Get full text

The challenge of follow-on biologics for treatment of multiple sclerosis by REINGOLD, S. C, STEINER, J. P, POLMAN, C. H, COHEN, J. A, FREEDMAN, M. S, KAPPOS, L, THOMPSON, A. J, WOLINSKY, J. S

“…Intellectual property protections for biologic medicinals for multiple sclerosis (MS) are beginning to expire, opening the possibility of development,…”
Get full text

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial by Rovaris, M., Comi, G., Rocca, MA, Valsasina, P., Ladkani, D., Pieri, E., Weiss, S., Shifroni, G., Wolinsky, JS, Filippi, M., European/Canadian Glatiramer Acetate Study Group

“…Glatiramer acetate (GA) is effective in reducing clinical and magnetic resonance imaging (MRI) activity in relapsing-remitting multiple sclerosis (RRMS)…”
Get full text

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data by Johnson, K. P., Ford, C. C., Lisak, R. P., Wolinsky, J. S.

“…Objective –  To assess the long‐term effectiveness of continuous glatiramer acetate (GA) therapy in relapsing‐remitting multiple sclerosis (RRMS). Methods – …”
Get full text

The relationship of MS to physical trauma and psychological stress : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by GOODIN, D. S, EBERS, G. C, JOHNSON, K. P, RODRIGUEZ, M, SIBLEY, W. A, WOLINSKY, J. S

Get full text